Abstract:18 Background: Hand foot syndrome (HFS) is a dose-limiting side effect of capecitabine in patients with breast cancer. Celecoxib, an oral cyclo-oxygenase-2 (COX-2) inhibitor is effective in reducing the incidence of capecitabine associated HFS. However, it has not been adopted in the clinics due to concerns regarding cardiac and gastrointestinal toxicity. We report the efficacy of topical diclofenac in prevention of capecitabine associated HFS in patients with breast cancer. Methods: In the D-ToRCH (Diclofenac-topical for reduction of capecitabine related HFS) trial, we randomized 264 patients with breast or gastrointestinal cancers planned to receive capecitabine to apply either 1% topical diclofenac or placebo gel. Stratified (male or female; capecitabine monotherapy or combination therapy), permuted variable size block randomization was done using a computer-generated random numbers sequence. The primary objective was to compare the incidence of grade 2 or higher HFS in diclofenac and placebo arms. Secondary objectives were incidence of any grade HFS, capecitabine dose reductions due to HFS and self-reported adherence with application. Here, we report the exploratory subgroup analysis of patients with breast cancer. Results: The breast cancer subgroup included 148 patients (77 in drug arm and 71 in placebo arm). Baseline characteristics were similar in both arms. Median age of overall population was 47 years (IQR 39-56). 89 patients (60.1%) had an ECOG (Eastern Co-operative Oncology Group) performance status of 0-1, while the rest had a score of 2. Hypothyroidism was the most common comorbidity (n=24, 16.2%). Majority received capecitabine monotherapy (n=95, 64.2%). The most common additional chemotherapy drug used was lapatinib (n=42, 79.3%). 60 patients had stage 3 disease (40.8%) and 88 patients had metastatic breast cancer (59.5%). Overall, 20 patients developed any grade HFS, of which 6 were in the diclofenac arm and 14 in placebo arm (7.8% vs 19.7%, p=0.034). Grade 2/3 HFS events were noted in 3 patients (3.9%) in diclofenac arm and 11 patients (15.5%) in placebo arm (p=0.016). Capecitabine dose reductions were less frequent in the diclofenac arm compared to placebo (3.9% vs 15.5%). Adherence to topical treatment was similar in both the study arm. Other adverse events of capecitabine like diarrhea, mucositis and myelosuppression were similar in both the arms. Conclusions: Topical diclofenac gel significantly reduced the incidence of all grades of HFS in breast cancer patients receiving capecitabine. Applying topical diclofenac led to less frequent capecitabine dose reductions. Moving forward, we feel this should be the new standard of care and use of topical diclofenac should be regularized in medical oncology outpatient departments. Clinical trial information: CTRI/2021/01/030592 .

Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial

Topical diclofenac in prevention of capecitabine associated HFS in patients with breast cancer: An exploratory subgroup analysis of the D-ToRCH study.

Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials

Chemotherapy-induced hand foot syndrome: comparative efficacy and safety of pharmacological prophylaxis – systematic review and Bayesian network meta-analysis

How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs

Hand–foot syndrome induced by chemotherapy drug: Case series study and literature review

Formulation design and optimization of novel soft glycerosomes for enhanced topical delivery of celecoxib and cupferron by Box-Behnken statistical design

Efficacy and Safety Profile of Celecoxib for Treating Advanced Cancers: A Meta-Analysis of 11 Randomized Clinical Trials

The preventive effect of celecoxib on regorafenib-associated hand-foot syndrome in patients with liver metastasis from colorectal cancer: A single-center, retrospective, real-world study.

Abstract 1131: Preventive effect of Celecoxib in Sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial

Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies

Optimizing quality of life: integrating palliative care for patients with hand-foot syndrome in oncology practice

Preparation, optimization and evaluation of transdermal therapeutic system of celecoxib to treat inflammation for treatment of rheumatoid arthritis

Optimizing and Evaluating the Transdermal Permeation of Hydrocortisone Transfersomes Formulation Based on Digital Analysis of the In Vitro Drug Release and Ex Vivo Studies

Topical henna and curcumin (Alpha®) ointment efficacy for prevention of capecitabine induced hand-foot syndrome: A randomized, triple-blinded, placebo-controlled clinical

Management of cytotoxic chemotherapy-induced hand-foot syndrome

Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study)

Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, and Parallel-Controlled Trial

Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients

Efficacy of Compound Traditional Chinese Medicine Oil in Alleviating Regorafenib-Induced Hand-Foot Skin Reaction.